Clinical Trial Update: Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome [Phase 3]

View source ↗

Summary

Phase 3 efficacy and safety study of arbaclofen (STX209) for social withdrawal in adolescents and adults with Fragile X syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• Arbaclofen (arbaclofen)

Snippet

Sponsor: Seaside Therapeutics, Inc. | Conditions: Fragile X Syndrome | Phase 3 | Status: COMPLETED